Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 11/2016

01-11-2016 | Health Services Review

Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?

Author: Peter K. K. Wong

Published in: Rheumatology International | Issue 11/2016

Login to get access

Abstract

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease which results in extensive articular and extra-articular morbidity and increased mortality from cardiovascular disease. Despite an increasing range of non-biological and biological disease-modifying agents, poor patient adherence with medication is a significant barrier to effective control of the inflammation associated with RA. This review seeks to identify factors that affect patient adherence with medication, examine the effectiveness of interventions to address this issue and offer practical suggestions to improve medication adherence. The impact of health literacy on medication adherence and the novel role of musculoskeletal ultrasound as an educational intervention will also be discussed.
Literature
1.
2.
Elliott RA (2008) Poor adherence to medication in adults with rheumatoid arthritis: reasons and solutions. Dis Manag Health Outcomes 16:13–29CrossRef
3.
Escalas C, Dalichampt M, Combe B, Fautrel B, Guillemin F, Durieux P, Dougados M, Ravaud P (2012) Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort. Ann Rheum Dis 71:1803–1808CrossRefPubMed
4.
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68:1–26
5.
van den Bemt B, van Lankveld W (2007) How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Prac Rheum 3:681CrossRef
6.
van den Bemt B, Zwikker H, van den Ende C (2012) Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Exp Rev Clin Immunol 8:337–351CrossRef
7.
Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R (2008) Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? Arthritis Rheum 59:1519–1526CrossRefPubMed
8.
Fallis BA, Dhalla IA, Klemensberg J, Bell CM (2013) Primary medication non-adherence after discharge from a general internal medicine service. PLoS One 8:e61735CrossRefPubMedPubMedCentral
9.
Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M (2009) Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability. Arthritis Res Ther 11:R26CrossRefPubMedPubMedCentral
10.
Hovstadius B, Petersson G (2011) Non-adherence to drug therapy and drug acquisition costs in a national population—a patient-based register study. BMC Health Serv Res 11:326CrossRefPubMedPubMedCentral
11.
De Vera MA (2014) Economics of non-adherence to biologic therapies in rheumatoid arthritis. Curr Rheum Rep 16:460CrossRef
12.
Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W (1999) Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 26:2114–2122PubMed
13.
Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A (2007) Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheum Int 27:743–746CrossRef
14.
15.
van den Bemt B, van den Hoogen F, Benraad B, Hekster Y, van Riel Y, van Lankveld W (2009) Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 36:2164–2170CrossRefPubMed
16.
Treharne GJ (2004) Medication adherence in rheumatoid arthritis: effects of psychosocial factors. Psychol Health Med 9:337–349CrossRef
17.
de Thurah A, Nørgaard M, Harder I, Stengaard-Pedersen K (2010) Compliance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine. A prospective cohort study. Rheum Int 30:1441–1448CrossRef
18.
Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN (2015) The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. Rheumatology (Oxford) 54:1780–1791CrossRef
19.
Hill J, Bird H, Johnson S (2001) Effect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 60:869–875PubMedPubMedCentral
20.
Müller R, Kallikorm R, Põlluste K, Lember M (2012) Compliance with treatment of rheumatoid arthritis. Rheum Int 32:3131–3135CrossRef
21.
Salt E, Peden A (2011) The complexity of the treatment: the decision-making process among women with rheumatoid arthritis. Qual Health Res 21:214–222CrossRefPubMed
22.
Kristensen LE, Saxne T, Nilsson JA, Geborek P (2006) Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8:R174CrossRefPubMedPubMedCentral
23.
Borah BJ, Huang X, Zarotsky V, Globe D (2009) Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs. Curr Med Res Opin 25:1365–1377CrossRefPubMed
24.
Poulos C, Hauber AB, González JM, Turpcu A (2014) Patients’ willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res (Hoboken) 66:1008–1015CrossRef
25.
Tkacz J, Ellis L, Bolge SC, Meyer R, Brady BL, Ruetsch C (2014) Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients. Clin Ther 36:737–747CrossRefPubMed
26.
Wong M, Mulherin D (2007) The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskelet Care 5:148–159CrossRef
27.
Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, Solomon DH (2014) Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis. J Rheumatol 41:2370–2378CrossRefPubMedPubMedCentral
28.
Neame R, Hammond A (2005) Beliefs about medications: a questionnaire survey of people with rheumatoid arthritis. Rheumatology (Oxford) 44:762–767CrossRef
29.
Goodacre LJ, Goodacre JA (2004) Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication. Rheumatology (Oxford) 43:583–586CrossRef
30.
de Thurah A, Nørgaard M, Johansen MB, Stengaard-Pedersen K (2010) Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheum 39:197–205CrossRefPubMed
31.
Contreras-Yáñez PonceDe, León S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V (2010) Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 340:282–290CrossRefPubMed
32.
Pascual-Ramos V, Contreras-Yáñez I (2013) Motivations for inadequate persistence with disease modifying anti-rheumatic drugs in early rheumatoid arthritis: the patient’s perspective. BMC Musculoskelet Disord 14:336CrossRefPubMedPubMedCentral
33.
Joplin S, van der Zwan R, Joshua F, Wong PK (2015) Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int 2015:150658. doi:10.​1155/​2015/​150658 (Epub 2015 Apr 28) CrossRefPubMedPubMedCentral
34.
35.
36.
37.
Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA (2010) Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health 13:805–812CrossRefPubMed
38.
Pasma A, van’t Spijker A, Hazes JM, Busschbach JJ, Luime JJ (2013) Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum 43:18–28CrossRefPubMed
39.
Ho M, Lavery B, Pullar T (1998) The risk of treatment. A study of rheumatoid arthritis patients’ attitudes. Br J Rheum 37:459–460CrossRef
40.
Berry D, Bradlow A, Bersellini E (2004) Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions. Rheumatology (Oxford) 43:901–905CrossRef
41.
Brus H, van de Laar MA, Taal E, Rasker JJ, Wiegman O (1998) Effects of patient education on compliance with basic treatment regimens and health in recent onset active rheumatoid arthritis. Ann Rheum Dis 57:146–151CrossRefPubMedPubMedCentral
42.
Niedermann K, Fransen J, Knols R, Uebelhart D (2004) Gap between short- and long-term effects of patient education in rheumatoid arthritis patients: a systematic review. Arthritis Rheum 51:388–398CrossRefPubMed
43.
Zwikker HE, van den Ende CH, van Lankveld WG, den Broeder AA, van den Hoogen FH, van de Mosselaar B, van Dulmen S, van den Bemt BJ (2014) Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: a randomized controlled trial. Patient Educ Couns 94:356–361CrossRefPubMed
44.
Horne R, Weinman J (1999) Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555–567CrossRefPubMed
45.
Treharne GJ, Lyons AC, Hale ED, Douglas KM, Kitas GD (2006) ‘Compliance’ is futile but is ‘concordance’ between rheumatology patients and health professionals attainable? Rheumatology (Oxford) 45:1–5CrossRef
46.
Australian Government (1991) Department of education employment and training. The Australian language and literacy policy. Australian Government, Canberra
47.
48.
Adams RJ, Appleton SL, Hill CL, Ruffin RE, Wilson DH (2009) Inadequate health literacy is associated with increased asthma morbidity in a population sample. J Allergy Clin Immunol 124:601–603CrossRefPubMed
49.
Rosas-Salazar C, Apter AJ, Canino G, Celedón JC (2012) Health literacy and asthma. J Allergy Clin Immunol 129:935–942CrossRefPubMed
50.
Schillinger D, Grumbach K, Piette J, Wang F, Osmond D, Daher C, Palacios J, Sullivan GD, Bindman AB (2002) Association of health literacy with diabetes outcomes. JAMA 288:475–482CrossRefPubMed
51.
Cavanaugh K, Huizinga MM, Wallston KA, Gebretsadik T, Shintani A, Davis D, Gregory RP, Fuchs L, Malone R, Cherrington A, Pignone M, DeWalt DA, Elasy TA, Rothman RL (2008) Association of numeracy and diabetes control. Ann Intern Med 148:737–746CrossRefPubMed
52.
Estrada CA, Martin-Hryniewica M, Peek BT, Collins C, Byrd JC (2004) Literacy and numeracy skills and anticoagulation control. Am J Med Sci 328:88–93CrossRefPubMed
53.
Baker DW, Wolf MS, Feinglass J, Thompson JA, Gazmararian JA, Huang J (2007) Health literacy and mortality among elderly persons. Arch Intern Med 167:1503–1509CrossRefPubMed
54.
Sudore RL, Yaffe K, Satterfield S, Harris TB, Mehta KM, Simonsick EM, Newman AB, Rosano C, Rooks R, Rubin SM, Ayonayon HN, Schillinger D (2006) Limited literacy and mortality in the elderly: the health, aging, and body composition study. J Gen Intern Med 21:806–812CrossRefPubMedPubMedCentral
55.
Miles S, Davis TC (1995) Patients who can’t read. Implications for the health care system. JAMA 274:1719–1720CrossRefPubMed
56.
American Medical Association (1999) Ad hoc committee on health literacy for the council on scientific affairs, health literacy: report of the council on scientific affairs. JAMA 281:552–557CrossRef
57.
Adams RJ (2010) Improving health outcomes with better patient understanding and education. J Risk Manag Health Care Policy 3:61–72CrossRef
58.
Caplan L, Wolfe F, Michaud K, Quinzanos I, Hirsh JM (2014) Strong association of health literacy with functional status among rheumatoid arthritis patients: a cross-sectional study. Arthritis Care Res (Hoboken) 66:508–514CrossRef
59.
Wong PK, Christie L, Johnston J, Bowling A, Freeman D, Joshua F, Bird P, Chia K, Bagga H (2014) How well do patients understand written instructions?: health literacy assessment in rural and urban rheumatology outpatients. Medicine (Baltimore) 93(25):e129. doi:10.​1097/​MD.​0000000000000129​ CrossRef
60.
Buchbinder R, Hall S, Youd JM (2006) Functional health literacy of patients with rheumatoid arthritis attending a community-based rheumatology practice. J Rheumatol 33:879–886PubMed
61.
Swearingen CJ, McCollum BA, Daltroy LH, Pincus T, Dewalt DA, Davis TC (2010) Screening for low literacy in a rheumatology setting: more than 10% of patients cannot read “cartilage,” “diagnosis,” “rheumatologist,” or “symptom”. J Clin Rheumatol 16:359–364CrossRefPubMed
62.
Gordon MM, Hampson R, Capell HA, Madhok R (2002) Illiteracy in rheumatoid arthritis patients as determined by the Rapid Estimate of Adult Literacy in Medicine (REALM) score. Rheumatology (Oxford) 41:750–754CrossRef
63.
Buchbinder R, Hall S, Grant G, Mylvaganam A, Patrick MR (2001) Readability and content of supplementary written drug information for patients used by Australian rheumatologists. Med J Aust 174:575–578PubMed
64.
Hirsh JM, Boyle DJ, Collier DH, Oxenfeld AJ, Nash A, Quinzanos I, Caplan L (2011) Limited health literacy is a common finding in a public health hospital’s rheumatology clinic and is predictive of disease severity. J Clin Rheum 17:236–241CrossRef
65.
Katz MG, Kripalani S, Weiss BD (2006) Use of pictorial aids in medication instructions: a review of the literature. Am J Health Syst Pharm 63:2391–2397CrossRefPubMed
66.
El Miedany Y, El Gaafary M, Palmer D (2012) Assessment of the utility of visual feedback in the treatment of early rheumatoid arthritis patients: a pilot study. Rheum Int 32:3061–3068CrossRef
67.
Joplin SK, van der Zwan R, Bagga H, Joshua F, Wong PK (2014) Pilot study assessing the novel use of musculoskeletal ultrasound in patients with rheumatoid arthritis to improve patient attitudes and adherence to medication. Int J Rheum Dis. doi:10.​1111/​1756-185X.​12402 PubMed
68.
Kumar K, Raza K, Gill P, Greenfield S (2016) The impact of using musculoskeletal ultrasound imaging and other influencing factors on medication adherence in patients with rheumatoid arthritis: a qualitative study. Patient Prefer Adherence 10:1091–1100CrossRefPubMedPubMedCentral
Metadata
Title
Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?
Author
Peter K. K. Wong
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 11/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3566-4

Other articles of this Issue 11/2016

Rheumatology International 11/2016 Go to the issue

Safety and Pharmacovigillance

Small intestinal injury in NSAID users suffering from rheumatoid arthritis or osteoarthritis

Food for Thought

Influence of patient personality in the treatment of rheumatoid arthritis

Genes and Disease

Prevalence and significance of MEFV gene mutations in patients with gouty arthritis

Health Services Research

Variability in the frequency of rheumatology consultations in patients with rheumatoid arthritis in Spain

Genes and Disease

Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis

Women Issues

Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits